TargetMol

Avitinib maleate

Product Code:
 
TAR-T3721
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T3721-5mg5mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3721-1mL1 mL * 10 mM (in DMSO)£143.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3721-10mg10mg£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3721-25mg25mg£246.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3721-50mg50mg£369.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3721-100mg100mg£550.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Avitinib maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (EGFR) inhibitor.
CAS:
1557268-88-8
Formula:
C30H30FN7O6
Molecular Weight:
603.611
Pathway:
JAK/STAT signaling; Angiogenesis; Tyrosine Kinase/Adaptors
Purity:
0.9977
SMILES:
OC(=O)C=C/C(O)=O.CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3cc[nH]c3n2)cc1F
Target:
EGFR

References

Vujic I, Sanlorenzo M, Esteve-Puig R, Vujic M, Kwong A, et al. Oncotarget. 2016 Feb 9;7(6):7297-306. Xu X. Parallel phase 1 clinical trials in the US and in China,et al.Chin J Cancer. 2015 Jul 8;34(7):285-7. Hulce JJ, Joslyn C, Speers AE,et al.Bethesda (MD): National Center for Biotechnology Information (US); 2010-.